KLRC1 and neoplasm: Because XPO1 is upregulated in tumors and selinexor selectively blocks translation in tumor cells (36), a potential advantage for blocking NKG2A:HLA-E interactions via selinexor rather than antibodies is that selinexor may retain expression of HLA-E on non-tumor cells.